SI1797037T1 - Postopek priprave 4-(4-((((4-kloro-3-(trifluorometil)fenil)amino)karbonil)amino) fenioksi)N-metilpiridin-2-karboksamida - Google Patents

Postopek priprave 4-(4-((((4-kloro-3-(trifluorometil)fenil)amino)karbonil)amino) fenioksi)N-metilpiridin-2-karboksamida

Info

Publication number: SI1797037T1
Authority: SI; Slovenia
Prior art keywords: phenylćaminoćcarbonyl; aminoćphenyoxyćn; methylpyridine; carboxamide; trifluoromethyl
Prior art date: 2004-09-29

Application number

SI200531947T

Other languages

English (en)

Inventor

Michael Logers

Reinhold Gehring

Oliver Kuhn

Mike Matthaus

Klaus Mohrs

Matthias Muller-Gliemann

Jurgen Stiehl

Mathias Berwe

Jana Lenz

Werner Heilmann

Original Assignee

Bayer Healthcare Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-09-29

Filing date

2005-09-20

Publication date

2015-06-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35457568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1797037(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-09-20 Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc

2015-06-30 Publication of SI1797037T1 publication Critical patent/SI1797037T1/sl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pyridine Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Developing Agents For Electrophotography (AREA)
Medicines Containing Plant Substances (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SI200531947T 2004-09-29 2005-09-20 Postopek priprave 4-(4-((((4-kloro-3-(trifluorometil)fenil)amino)karbonil)amino) fenioksi)N-metilpiridin-2-karboksamida SI1797037T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP04023131		2004-09-29
EP05794785.5A EP1797037B1 (en)	2004-09-29	2005-09-20	Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenyoxy}n-methylpyridine-2-carboxamide
PCT/EP2005/010118 WO2006034796A1 (en)	2004-09-29	2005-09-20	Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n-methylpyridine-2-carboxamide

Publications (1)

Publication Number	Publication Date
SI1797037T1 true SI1797037T1 (sl)	2015-06-30

Family

ID=35457568

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI200531947T SI1797037T1 (sl)	2004-09-29	2005-09-20	Postopek priprave 4-(4-((((4-kloro-3-(trifluorometil)fenil)amino)karbonil)amino) fenioksi)N-metilpiridin-2-karboksamida

Country Status (34)

Country	Link
US (1)	US8124782B2 (sl)
EP (1)	EP1797037B1 (sl)
JP (2)	JP2008514657A (sl)
KR (1)	KR101263032B1 (sl)
CN (1)	CN101052619B (sl)
AR (1)	AR053973A1 (sl)
AU (1)	AU2005289099B2 (sl)
BR (1)	BRPI0515944B1 (sl)
CA (1)	CA2581835C (sl)
CU (1)	CU23754B7 (sl)
CY (1)	CY1116126T1 (sl)
DK (1)	DK1797037T3 (sl)
DO (1)	DOP2005000183A (sl)
EC (1)	ECSP077357A (sl)
ES (1)	ES2532377T3 (sl)
GT (1)	GT200500269A (sl)
HN (1)	HN2005000768A (sl)
HR (1)	HRP20150295T1 (sl)
IL (1)	IL182046A0 (sl)
MA (1)	MA28883B1 (sl)
MY (1)	MY149873A (sl)
NO (1)	NO339647B1 (sl)
NZ (1)	NZ554119A (sl)
PE (5)	PE20091585A1 (sl)
PL (1)	PL1797037T3 (sl)
PT (1)	PT1797037E (sl)
SG (1)	SG155997A1 (sl)
SI (1)	SI1797037T1 (sl)
SV (1)	SV2006002243A (sl)
TW (1)	TWI382973B (sl)
UA (1)	UA90691C2 (sl)
UY (1)	UY29143A1 (sl)
WO (1)	WO2006034796A1 (sl)
ZA (1)	ZA200702511B (sl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE538794T1 (de)	1999-01-13	2012-01-15	Bayer Healthcare Llc	Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
US8124630B2 (en)	1999-01-13	2012-02-28	Bayer Healthcare Llc	ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
MXPA04007832A (es)	2002-02-11	2005-09-08	Bayer Pharmaceuticals Corp	Aril-ureas con actividad inhibitoria de angiogenesis.
EP1636585B2 (en)	2003-05-20	2012-06-13	Bayer HealthCare LLC	Diaryl ureas with kinase inhibiting activity
HRP20060073B1 (hr)	2003-07-23	2014-03-14	Bayer Healthcare Llc	Fluoro supstituirana omega-karboksiaril difenil urea za lijeäśenje i prevenciju bolesti i stanja
BRPI0515944B1 (pt)	2004-09-29	2021-11-09	Bayer Healthcare Llc	Processo para a preparação de 4-{4-[({[4-cloro-3-(trifluorometil)fe-nil]amino}carbonil) amino]fenóxi}nmetilpiridina-2-carboxamida
PL1797038T3 (pl)	2004-09-29	2012-11-30	Bayer Healthcare Llc	Termodynamicznie trwała postać tosylanu bay 43-9006
CN104688697A (zh)	2005-03-07	2015-06-10	拜尔健康护理有限责任公司	用于治疗癌症的包含ω-羧芳基取代的二苯基脲的药物组合物
AR062927A1 (es)	2006-10-11	2008-12-17	Bayer Healthcare Ag	4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
WO2008058644A1 (en) *	2006-11-14	2008-05-22	Bayer Schering Pharma Aktiengesellschaft	Polymorph ii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
NZ583790A (en) *	2007-09-10	2012-04-27	Cipla Ltd	Process for the preparation the raf kinase inhibitor sorafenib and intermediates for use in the process
WO2009054004A2 (en) *	2007-10-22	2009-04-30	Natco Pharma Limited	Process for the preparation of sorafenib
EP2231612A1 (en)	2008-01-17	2010-09-29	Sicor, Inc.	Polymorph form iii of sorafenib tosylate, sorafenib tosylate methanol solvate and sorafenib tosylate ethanol solvate, and processes for preparation thereof
WO2009111061A1 (en) *	2008-03-06	2009-09-11	Sicor Inc.	Process for the preparation of sorafenib and salts thereof
CN103254126A (zh) *	2008-09-19	2013-08-21	苏州泽璟生物制药有限公司	氘代的ω-二苯基脲及衍生物以及包含该化合物的药物组合物
AU2010299483B2 (en) *	2009-09-24	2014-08-28	Sun Pharmaceutical Industries Limited	Process for the preparation of sorafenib tosylate
US8604208B2 (en)	2009-09-24	2013-12-10	Ranbaxy Laboratories Limited	Polymorphs of sorafenib acid addition salts
US8552197B2 (en) *	2009-11-12	2013-10-08	Ranbaxy Laboratories Limited	Sorafenib ethylsulfonate salt, process for preparation and use
WO2011076711A2 (en)	2009-12-23	2011-06-30	Ratiopharm Gmbh	Polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methylpyridine-2-carboxamide
PL2528899T3 (pl)	2010-01-29	2015-02-27	Ranbaxy Laboratories Ltd	Solwat sorafenibu z dimetylosulfotlenkiem
CN102190616B (zh) *	2010-03-18	2015-07-29	苏州泽璟生物制药有限公司	一种氘代的ω-二苯基脲的合成及生产的方法和工艺
AR081060A1 (es)	2010-04-15	2012-06-06	Bayer Schering Pharma Ag	Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
CN102617458A (zh) *	2010-05-18	2012-08-01	张南	抗癌用化合物的制备方法
WO2012012404A1 (en)	2010-07-19	2012-01-26	Bayer Healthcare Llc	Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
AU2011310532B2 (en)	2010-10-01	2016-01-14	Bayer Intellectual Property Gmbh	Substituted N-(2-arylamino)aryl sulfonamide-containing combinations
WO2012071425A1 (en)	2010-11-22	2012-05-31	Teva Pharmaceutical Industries Ltd.	Solid state forms of sorafenib besylate, and processes for preparations thereof
EP2559431A1 (en)	2011-08-17	2013-02-20	Ratiopharm GmbH	Pharmaceutical composition comprising 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
CN103664771B (zh) *	2012-09-19	2016-03-30	齐鲁制药有限公司	索拉非尼的晶型a及其制备方法
WO2014118807A1 (en) *	2013-02-04	2014-08-07	Intas Pharmaceuticals Limited	A novel process for the preparation of sorafenib tosylate form iii
CN104710354A (zh) *	2013-12-13	2015-06-17	江苏豪森药业股份有限公司	高纯度索拉非尼的制备方法
CN104761492A (zh) *	2014-01-03	2015-07-08	正大天晴药业集团股份有限公司	对甲苯磺酸索拉非尼的晶型及其制备方法
CN104177292A (zh) *	2014-08-08	2014-12-03	亿腾药业（泰州）有限公司	一种工业化生产甲苯磺酸索拉非尼多晶型ⅰ的方法
CN105439947A (zh) *	2014-12-01	2016-03-30	石药集团中奇制药技术（石家庄）有限公司	一种甲苯磺酸索拉非尼新晶型及其制备方法
EP3109236B1 (en)	2015-06-23	2017-08-09	F.I.S.- Fabbrica Italiana Sintetici S.p.A.	Scalable process for the preparation of sorafenib tosylate ethanol solvate and sorafenib tosylate form iii
CN105181844A (zh) *	2015-09-11	2015-12-23	江苏嘉逸医药有限公司	一种高效液相色谱法测定甲苯磺酸索拉非尼含量和有关物质的方法
CN105585523A (zh) *	2015-12-29	2016-05-18	上海北卡医药技术有限公司	一种对甲苯磺酸索拉非尼的新晶型及其制备方法和用途
CN107840823B (zh) *	2016-09-20	2021-08-17	意大利合成制造有限公司	用于制备甲苯磺酸索拉非尼乙醇溶剂化物和iii型甲苯磺酸索拉非尼的可变规模的方法
CN107915676A (zh) *	2017-10-26	2018-04-17	魏海霞	索拉非尼的制备方法
CN109796400B (zh) *	2017-11-16	2022-07-29	四川科伦药物研究院有限公司	一种甲苯磺酸索拉菲尼晶型及其制备方法
CN113773249A (zh) *	2020-06-10	2021-12-10	杭州中美华东制药有限公司	索拉非尼游离碱晶型Form X及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
LU86960A1 (fr) *	1987-07-31	1989-03-08	Oreal	Procede de preparation de piperidino-6 diamino-2,4 pyrimidine oxyde-3 et composes nouveaux
JPH02934A (ja) *	1988-05-27	1990-01-05	Konica Corp	非線形光学材料
JP2971291B2 (ja) *	1993-06-02	1999-11-02	田辺製薬株式会社	光学活性２−アミノ酪酸の製法
JP3866323B2 (ja) *	1996-03-27	2007-01-10	ポーラ化成工業株式会社	新規ｎ−ベンジルベンズアミド誘導体
JPH09316069A (ja) *	1996-03-28	1997-12-09	Ajinomoto Co Inc	新規キサントン誘導体
US8124630B2 (en)	1999-01-13	2012-02-28	Bayer Healthcare Llc	ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
SK287419B6 (sk) *	1999-01-13	2010-09-07	Bayer Corporation	Použitie difenylových močovín substituovaných omega-karboxyarylovou skupinou ako inhibítorov rafkinázy
WO2000042012A1 (en)	1999-01-13	2000-07-20	Bayer Corporation	φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
GB2367816A (en) *	2000-10-09	2002-04-17	Bayer Ag	Urea- and thiourea-containing derivatives of beta-amino acids
ES2400070T3 (es)	2001-12-03	2013-04-05	Bayer Healthcare Llc	Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos
US20030207872A1 (en) *	2002-01-11	2003-11-06	Bayer Corporation	Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
DE10203086A1 (de) *	2002-01-28	2003-07-31	Bayer Ag	5-Ring Heterozyklen
MXPA04007832A (es) *	2002-02-11	2005-09-08	Bayer Pharmaceuticals Corp	Aril-ureas con actividad inhibitoria de angiogenesis.
EP1554289B1 (en) *	2002-08-13	2011-03-09	Sandoz Ag	A cefdinir intermediate
ATE374199T1 (de) *	2002-10-21	2007-10-15	Kirin Brewery	N-ä2-chlor-4-((6,7-dimethoxy-4- chinolyl)oxy)phenylü-n'-(5-methyl-3- isoxazolyl)harnstoffsalzin kristalliner form
EP1636585B2 (en)	2003-05-20	2012-06-13	Bayer HealthCare LLC	Diaryl ureas with kinase inhibiting activity
BRPI0515944B1 (pt)	2004-09-29	2021-11-09	Bayer Healthcare Llc	Processo para a preparação de 4-{4-[({[4-cloro-3-(trifluorometil)fe-nil]amino}carbonil) amino]fenóxi}nmetilpiridina-2-carboxamida

2005
- 2005-09-20 BR BRPI0515944-0A patent/BRPI0515944B1/pt active IP Right Grant
- 2005-09-20 EP EP05794785.5A patent/EP1797037B1/en not_active Expired - Lifetime
- 2005-09-20 DK DK05794785T patent/DK1797037T3/en active
- 2005-09-20 NZ NZ554119A patent/NZ554119A/en not_active IP Right Cessation
- 2005-09-20 UA UAA200704750A patent/UA90691C2/ru unknown
- 2005-09-20 KR KR1020077009652A patent/KR101263032B1/ko not_active Expired - Lifetime
- 2005-09-20 JP JP2007533904A patent/JP2008514657A/ja active Pending
- 2005-09-20 CA CA2581835A patent/CA2581835C/en not_active Expired - Lifetime
- 2005-09-20 SG SG200906449-4A patent/SG155997A1/en unknown
- 2005-09-20 PL PL05794785T patent/PL1797037T3/pl unknown
- 2005-09-20 AU AU2005289099A patent/AU2005289099B2/en not_active Ceased
- 2005-09-20 HR HRP20150295TT patent/HRP20150295T1/hr unknown
- 2005-09-20 SI SI200531947T patent/SI1797037T1/sl unknown
- 2005-09-20 ES ES05794785.5T patent/ES2532377T3/es not_active Expired - Lifetime
- 2005-09-20 PT PT05794785T patent/PT1797037E/pt unknown
- 2005-09-20 CN CN2005800373684A patent/CN101052619B/zh not_active Expired - Lifetime
- 2005-09-20 US US11/664,332 patent/US8124782B2/en active Active
- 2005-09-20 WO PCT/EP2005/010118 patent/WO2006034796A1/en not_active Ceased
- 2005-09-23 DO DO2005000183A patent/DOP2005000183A/es unknown
- 2005-09-26 AR ARP050104020A patent/AR053973A1/es active IP Right Grant
- 2005-09-27 MY MYPI20054553A patent/MY149873A/en unknown
- 2005-09-28 PE PE2009000510A patent/PE20091585A1/es active IP Right Grant
- 2005-09-28 TW TW094133620A patent/TWI382973B/zh not_active IP Right Cessation
- 2005-09-28 PE PE2009000511A patent/PE20091586A1/es not_active Application Discontinuation
- 2005-09-28 PE PE2005001144A patent/PE20060825A1/es active IP Right Grant
- 2005-09-28 PE PE2009000512A patent/PE20091587A1/es active IP Right Grant
- 2005-09-28 UY UY29143A patent/UY29143A1/es not_active IP Right Cessation
- 2005-09-28 PE PE2009000509A patent/PE20091584A1/es active IP Right Grant
- 2005-09-28 GT GT200500269A patent/GT200500269A/es unknown
- 2005-09-29 SV SV2005002243A patent/SV2006002243A/es active IP Right Grant
- 2005-10-04 HN HN2005000768A patent/HN2005000768A/es unknown
2007
- 2007-03-20 IL IL182046A patent/IL182046A0/en active IP Right Grant
- 2007-03-26 CU CU20070069A patent/CU23754B7/es active IP Right Grant
- 2007-03-27 ZA ZA200702511A patent/ZA200702511B/en unknown
- 2007-03-28 EC EC2007007357A patent/ECSP077357A/es unknown
- 2007-03-30 MA MA29788A patent/MA28883B1/fr unknown
- 2007-04-26 NO NO20072173A patent/NO339647B1/no unknown
2012
- 2012-11-02 JP JP2012242831A patent/JP5583190B2/ja not_active Expired - Lifetime
2015
- 2015-03-17 CY CY20151100268T patent/CY1116126T1/el unknown

Also Published As

Publication number	Publication date
BRPI0515944A (pt)	2008-08-12
EP1797037A1 (en)	2007-06-20
SG155997A1 (en)	2009-10-29
MY149873A (en)	2013-10-31
ES2532377T3 (es)	2015-03-26
PE20091587A1 (es)	2009-11-05
DK1797037T3 (en)	2015-03-30
CU20070069A7 (es)	2010-11-27
US8124782B2 (en)	2012-02-28
PE20091584A1 (es)	2009-10-28
PE20060825A1 (es)	2006-10-20
AU2005289099A1 (en)	2006-04-06
TW200626551A (en)	2006-08-01
NO20072173L (no)	2007-06-14
CA2581835C (en)	2012-12-18
CA2581835A1 (en)	2006-04-06
ZA200702511B (en)	2008-07-30
HK1113484A1 (en)	2008-10-03
HN2005000768A (es)	2010-09-17
PT1797037E (pt)	2015-03-17
AU2005289099B2 (en)	2012-07-19
JP2008514657A (ja)	2008-05-08
UY29143A1 (es)	2006-04-28
CU23754B7 (es)	2012-01-31
MA28883B1 (fr)	2007-09-03
CN101052619A (zh)	2007-10-10
KR101263032B1 (ko)	2013-05-09
JP5583190B2 (ja)	2014-09-03
JP2013067625A (ja)	2013-04-18
KR20070058676A (ko)	2007-06-08
IL182046A0 (en)	2007-07-24
UA90691C2 (en)	2010-05-25
DOP2005000183A (es)	2006-03-31
HRP20150295T1 (hr)	2015-05-22
US20080262236A1 (en)	2008-10-23
NZ554119A (en)	2010-07-30
EP1797037B1 (en)	2014-12-17
CN101052619B (zh)	2012-02-22
ECSP077357A (es)	2007-04-26
AR053973A1 (es)	2007-05-30
SV2006002243A (es)	2006-10-13
PL1797037T3 (pl)	2015-07-31
TWI382973B (zh)	2013-01-21
WO2006034796A1 (en)	2006-04-06
PE20091586A1 (es)	2009-10-31
PE20091585A1 (es)	2009-10-31
BRPI0515944B1 (pt)	2021-11-09
NO339647B1 (no)	2017-01-16
GT200500269A (es)	2006-05-11
CY1116126T1 (el)	2017-02-08

Publication	Publication Date	Title
SI1797037T1 (sl)	2015-06-30	Postopek priprave 4-(4-((((4-kloro-3-(trifluorometil)fenil)amino)karbonil)amino) fenioksi)N-metilpiridin-2-karboksamida
TWI340137B (en)	2011-04-11	Preparation process
IL173456A0 (en)	2006-06-11	Process for the preparation of 4-amino-3-quinolinecarbonitriles
IL168170A (en)	2010-12-30	Process for the preparation of roflumilast
IL188330A0 (en)	2008-04-13	Processes for the preparation of
IL181129A0 (en)	2007-07-04	Process for the preparation of polymorphs of mesotrione
ZA200804264B (en)	2009-01-28	Process for the preparation of ferri-succinylcasein
TWI367257B (en)	2012-07-01	Process for the preparation of 2-butanol
PT1748990E (pt)	2008-09-10	Processo para a preparação de telmisartan
SI1844036T1 (sl)	2015-12-31	Postopek za pripravo aripiprazola
GB2436262B (en)	2010-01-20	Process for the preparation of pantoprazole sodium
IL182421A0 (en)	2007-07-24	Process for the preparation of pyrazoles
GB0406635D0 (en)	2004-04-28	Process for the preparation of an emulsion
PL1763508T3 (pl)	2011-12-30	Sposób wytwarzania mocznika
ZA200601910B (en)	2006-11-29	Process for the preparation of organosilances
IL177561A0 (en)	2006-12-10	Process for the preparation of enantiomerically pure 1-substituted-3-aminoalcohols
TWI347945B (en)	2011-09-01	Process for the preparation of thiazolopyrimidines
IL191052A0 (en)	2008-12-29	Process for the preparation of tamsulosin and related compounds
HU0401379D0 (en)	2004-09-28	Process for the preparation of risperidon
PL378094A1 (pl)	2006-05-29	Sposób wytwarzania aldehydów
IL178960A0 (en)	2007-03-08	Process for the preparation of pyridin-2-ylmethylsulphinyl-1h-benzimidazol compounds
IL177353A0 (en)	2006-12-10	Process for the preparation of aq4n
GB0415076D0 (en)	2004-08-04	Process for the preparation of gabapentin
ZA200509495B (en)	2009-03-25	Process for the preparation of nicotinaldehydes
ZA200606688B (en)	2008-01-08	Process for the preparation of tryptase inhibitors